All In Biotech

Drug Trial Radar · NCT02992457

Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection

Study of the Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With and Without Post-hepatitis C Cirrhosis

Last checked: Nov 19, 2026Latest source record: Aug 25, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 10,000 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

10,000

Actual

Start

Jan 2015

Primary completion

Dec 2018

Study completion Dec 2019

Sponsor

Lead sponsor
Tanta UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 14, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Egypt has the highest prevalence of hepatitis C virus (HCV) in the world, estimated nationally at 14.7%. Genotype 4 (and subtype 4a in particular) dominates the HCV epidemic in Egypt. For decades the antiviral therapy of chronic HCV infection was based on the administration of Interferon(IFN), initially alone and then in combination with Ribavirin (RBV), but this regimen was effective in only 50% of patients with genotype 1, with significant side effects.

Conditions

  • Hepatitis C

Interventions

  • SofosbuvirDrug

    Sofosbuvir 400 mg daily.

  • RibavirinDrug

    Ribavirin 1000-1200 mg daily

  • Pegylated-interferon alfa-2aDrug

    Pegylated interferon alfa-2a once weekly for 3 months

  • SimeprevirDrug

    Olysio once daily.

  • DaclatasvirDrug

    Dakla once daily for three months.

  • Ritaprevir, paritaprevir, ombetasvirDrug

    Querevo for three months

  • Sofosbuvir and LedipasvirDrug

    Once daily for three months

  • Salvage therapyDrug

    three months in repeated treatment failure

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients with sustained virological response.Time frame: 2 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Sherief Abd-Elsalam

    Tanta, Egypt

  • Tanta university hospital

    Tanta, Egypt

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.